Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

29.51 +0.77 (+2.68%)

Delayed Quote Updated: 1:10 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zymeworks Inc. - Common Stock

< Previous 1 2 Next >

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside ↗

October 27, 2026

Zymeworks (NASDAQ:ZYME) outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its...

Via MarketBeat

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook ↗

October 02, 2026

Zymeworks (NASDAQ:ZYME) said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax...

Via MarketBeat

Zymeworks Q1 Earnings Call Highlights ↗

May 09, 2026

Zymeworks (NASDAQ:ZYME) reported a wider first-quarter loss as revenue declined from year-earlier milestone payments, while management highlighted regulatory catalysts for zanidatamab, progress across...

Via MarketBeat

Topics Earnings

Zymeworks (NASDAQ:ZYME) Misses Q1 Estimates But August PDUFA Date for Zanidatamab Offers Key Regulatory Catalyst ↗

May 07, 2026

Via Chartmill

Zymeworks Inc (NASDAQ:ZYME) Posts Wider Q4 Loss Despite Strategic Progress and Royalty Deal ↗

March 02, 2026

Via Chartmill

ZYMEWORKS INC (NASDAQ:ZYME) Fits the Minervini Trend Template with High Growth Momentum ↗

January 01, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

5 Analysts Have This To Say About Zymeworks ↗

October 24, 2025

Via Benzinga

Zymeworks (ZYME) Q1 2026 Earnings Transcript ↗

May 07, 2026

Zymeworks (ZYME) Q1 2026 Earnings Transcript

Via The Motley Fool

Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗

April 26, 2026

This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.

Via The Motley Fool

Topics Regulatory Compliance

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Wondering what's happening in today's pre-market session? ↗

March 09, 2026

Via Chartmill

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading...

Via Benzinga

Topics Stocks

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Zymeworks (ZYME) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Which stocks are moving after the closing bell on Tuesday? ↗

December 02, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Zymeworks Stock Sees Surge In Retail Chatter After Royalty Pivot, Cancer Trial Win Sparks Target Price Hikes ↗

November 24, 2025

Strong new Phase 3 Ziihera data boosted confidence in upcoming regulatory milestones.

Via Stocktwits

Alphabet To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 18, 2025

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

November 17, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 17, 2025

Via Benzinga

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

November 17, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays

November 17, 2025

U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

November 17, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗

November 11, 2025

Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate.

Via Chartmill

Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗

November 06, 2025

Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data.

Via Chartmill

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 14, 2025

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.